Trial Profile
Combination Immunotherapy With Ipilimumab and Nivolumab Plus a Dendritic Cell Based p53 Vaccine (Ad.p53-DC) in Patients With Relapsed Small Cell Lung Cancer (SCLC)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 04 Apr 2023
Price :
$35
*
At a glance
- Drugs INGN 225 (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 13 May 2022 Planned primary completion date changed from 1 Apr 2022 to 1 Dec 2022.
- 04 Jan 2022 Planned primary completion date changed from 1 Dec 2021 to 1 Apr 2022.
- 12 Jul 2021 Planned End Date changed from 1 Apr 2024 to 1 Dec 2023.